NEW YORK (GenomeWeb News) – German biotech firm Protagen said today that it has sold its subsidiary Protagen Protein Services to venture capital fund Zukunftsfond Heilbronn.

The sale will provide Protagen with funds to support its diagnostic development efforts, the company said. Financial and other terms of the deal were not disclosed.

Spun out as a 100 percent subsidiary of Protagen in January 2012, Protagen Protein Services offers a variety of protein analysis services aimed at academic labs as well as biopharmaceutical and biosimilars work.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Cell this week: map of human protein interactions, mutant phenotype variability in organisms of the same species from different genetic backgrounds, and more.

Critics call the Fred Hutchinson Cancer Research Center's Gary Gilliland's prediction of cancer cures within 10 years "out of touch with reality" and "irresponsible."

Ivan Oransky discusses the need for reproducibility research at The Conversation.

The San Diego Union-Tribune posts videos from Biocom's Speaker Series with Illumina's Jay Flatley, who discusses Roche's failed hostile takeover bid.